Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 6/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21530266 | 1.00 | NR1H2 (0.53) | NR1H2CHRM2CHRM1CHRM3TACR1 | |
| SCHEMBL26999246 | 1.00 | NR1H2 (0.53) | NR1H2CHRM2CHRM1CHRM3TACR1 | |
| SCHEMBL1340048 | 1.00 | NR1H2 (0.53) | NR1H2CHRM2CHRM1CHRM3TACR1 | |
| SCHEMBL2928958 | 1.00 | NR1H2 (0.53) | NR1H2CHRM2CHRM1CHRM3TACR1 | |
| SCHEMBL20214954 | 1.00 | NR1H2 (0.53) | NR1H2CHRM2CHRM1CHRM3TACR1 | |
| SCHEMBL13871086 | 1.00 | NR1H2 (0.53) | NR1H2CHRM2CHRM1CHRM3TACR1 | |
| SCHEMBL21554826 | 1.00 | NR1H2 (0.53) | NR1H2CHRM2CHRM1CHRM3TACR1 | |
| SCHEMBL21530267 | 1.00 | NR1H2 (0.53) | NR1H2CHRM2CHRM1CHRM3TACR1 | |
| SCHEMBL496608 | 0.91 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3TACR1 | |
| SCHEMBL2929834 | 0.88 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012570-A1 | BICYCLIC COMPOUND USED AS SELECTIVE ANDROGEN RECEPTOR MODULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012570-A1 | BICYCLIC COMPOUND USED AS SELECTIVE ANDROGEN RECEPTOR MODULATOR | AR, NR5A1, CYP17A1 | NR1H2 36/4885CHRM2 2055/4885CHRM1 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.